Free Trial

Sinovac Biotech (SVA) 10K Form and Latest SEC Filings 2026

Sinovac Biotech logo
$6.47 0.00 (0.00%)
As of 05/4/2026

Latest Sinovac Biotech SEC Filings & Recent Activity

Sinovac Biotech (NASDAQ:SVA) has submitted 158+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 3 submitted on April 17, 2026.

DateFilerForm TypeView
04/17/2026 5:10 AM
Li Jiaqiang (2126217) Reporting
Sinovac Biotech (1084201) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:21 AM
LO YUK LAM (2112689) Reporting
Sinovac Biotech (1084201) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:23 AM
JIAO SHUGE (2113196) Reporting
Sinovac Biotech (1084201) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:34 AM
LI JING (0) NMN
Sinovac Biotech (1084201) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:10 AM
ANDERSON SIMON (1263580) Reporting
Sinovac Biotech (1084201) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:11 AM
FU SHAN (2114111) Reporting
Sinovac Biotech (1084201) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:25 AM
Sinovac Biotech (1084201) Issuer
WANG YU (0) NMN
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:28 AM
Sinovac Biotech (1084201) Issuer
WANG NAN (2113113) Reporting
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:29 AM
GAO QIANG (0) NMN
Sinovac Biotech (1084201) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/18/2026 7:32 AM
Sinovac Biotech (1084201) Issuer
Yang Guang (0) Helen
Form 3
Initial statement of beneficial ownership of securities  
01/30/2026 2:23 PM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2026 2:23 PM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2026 2:23 PM
SAIF Partners IV L.P. (1472789) Filed by
Sinovac Biotech (1084201) Subject
Form SCHEDULE 13D/A
01/30/2026 2:23 PM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2026 2:23 PM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2026 2:24 PM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/30/2026 2:24 PM
1Globe Capital LLC (1562189) Filed by
Sinovac Biotech (1084201) Subject
Form SCHEDULE 13D/A
01/30/2026 2:24 PM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/15/2025 5:19 AM
Sinovac Biotech (1084201) Subject
WEIDONG YIN (1264738) Filed by
Form SCHEDULE 13D/A
07/14/2025 5:16 AM
Advantech Capital L.P. (1650757) Filed by
Sinovac Biotech (1084201) Subject
Form SCHEDULE 13D/A
07/14/2025 5:03 AM
SAIF Partners IV L.P. (1472789) Filed by
Sinovac Biotech (1084201) Subject
Form SCHEDULE 13D/A
07/11/2025 4:35 PM
Sinovac Biotech (1084201) Subject
Vivo Capital VIII, LLC (1618789) Filed by
Form SCHEDULE 13D/A
07/10/2025 8:54 PM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/09/2025 8:53 PM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/09/2025 8:55 PM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/08/2025 8:14 AM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/07/2025 8:41 PM
1Globe Capital LLC (1562189) Filed by
Sinovac Biotech (1084201) Subject
Form SCHEDULE 13D/A
07/03/2025 8:47 PM
1Globe Capital LLC (1562189) Filed by
Sinovac Biotech (1084201) Subject
Form SCHEDULE 13D/A
07/01/2025 9:56 AM
1Globe Capital LLC (1562189) Filed by
Sinovac Biotech (1084201) Subject
Form SCHEDULE 13D/A
06/30/2025 6:00 AM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/25/2025 5:05 AM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/20/2025 5:43 AM
Sinovac Biotech (1084201) Subject
WEIDONG YIN (1264738) Filed by
Form SCHEDULE 13D/A
06/18/2025 8:04 PM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/18/2025 1:09 PM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/18/2025 7:03 AM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/17/2025 5:06 AM
SAIF Partners IV L.P. (1472789) Filed by
Sinovac Biotech (1084201) Subject
Form SCHEDULE 13D/A
06/13/2025 5:26 PM
Sinovac Biotech (1084201) Subject
Vivo Capital VIII, LLC (1618789) Filed by
Form SCHEDULE 13D/A
05/23/2025 5:11 AM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/20/2025 5:08 AM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/19/2025 5:02 AM
Sinovac Biotech (1084201) Filer
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)

Sinovac Biotech SEC Filings - Frequently Asked Questions

Sinovac Biotech (SVA) has submitted 158+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Sinovac Biotech's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 3 submitted on April 17, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:SVA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners